Reata Financial Statements From 2010 to 2024
| RETADelisted Stock | USD 109.67 3.31 2.93% |
Check Reata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reata Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Reata financial statements analysis is a perfect complement when working with Reata Pharmaceuticals Valuation or Volatility modules.
Reata |
Reata Pharmaceuticals Company Return On Equity Analysis
Reata Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Reata Pharmaceuticals Return On Equity | -1.12 |
Most of Reata Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Reata Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Reata Pharmaceuticals has a Return On Equity of -1.1239. This is 95.31% lower than that of the Pharmaceuticals sector and 96.92% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Reata Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Reata Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reata Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Reata Pharmaceuticals competition to find correlations between indicators driving Reata Pharmaceuticals's intrinsic value. More Info.Reata Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Reata Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Reata Pharmaceuticals Financial Statements
Reata Pharmaceuticals stakeholders use historical fundamental indicators, such as Reata Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Reata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Reata Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Reata Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Reata Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |